The effect of synthetic muramyl dipeptide on glycosaminoglycan synthesis in cultured rat costal chondrocytes was examined. Muramyl dipeptide alone had no effect on the glycosaminoglycan synthesis of rat chondrocytes, whereas Escherichia coli lipopolysaccharide and interleukin ila inhibited glycosaminoglycan synthesis in a dose dependent manner. Muramyl dipeptide, when added to chondrocyte cultures in the presence of lipopolysaccharide, enhanced the lipopolysaccharide induced inhibition of glycosaminoglycan synthesis in a dose dependent manner. Adjuvant active analogues of muramyl dipeptide, but not adjuvant inactive analogues, also enhanced the lipopolysaccharide induced inhibition of glycosaminoglycan synthesis. In combination with muramyl dipeptide, to inhibit glycosaminoglycan synthesis, lipopolysaccharide could be replaced with the synthetic lipid A, an active principle of lipopolysaccharide. These results show that the muramyl dipeptide portion ofbacterial peptidoglycan enhances the susceptibility of rat chondrocytes to the lipid A portion of bacterial lipopolysaccharide, and therefore the interaction between chondrocytes and bacterial cell wail components might be involved in damaging the cartilage in inflammatory joint diseases.
Destruction of the articular cartilage is one feature of inflammatory joint diseases such as rheumatoid arthritis. Bacterial cell wall components linked to the infection may trigger a breakdown in cartilage as lipopolysaccharide, a major component of the cell wall of Gram negative bacteria, stimulates macrophages to release interleukin 1 (IL-1)1 and tumour necrosis factor a,2 cytokines which promote cartilage breakdown and inhibit the synthesis of cartilage matrix. 3 4 In addition, it seems likely that lipopolysaccharide itself enhances the cartilage breakdown and reduces re-synthesis through a direct mechanism. 5 Peptidoglycan is a major cell wall component of bacteria. N-Acetylmuramyl-L-alanyl-D-isoglutamine or muramyl dipeptide is an essential component for a number of biological activities of bacterial cell wall peptidoglycan, including immunoadjuvant activity,6-' induction of adjuvant arthritis,"1 enhancement of collagen induced arthritis,'2 bone resorption,'3 stimulation of IL-I production,'4 and macrophage colony stimulating factor production.' 5 16 We reported that muramyl dipeptide inhibits glycosaminoglycan synthesis and promotes the release of glycosaminoglycan from the cell layer into the medium in cultures of rabbit costal chondrocytes,'7 findings which suggested that muramyl dipeptide and lipopolysaccharide are important factors related to the destruction of cartilage.
We now report evidence that in rat chondrocytes muramyl dipeptide alone has no effect on glycosaminoglycan synthesis, yet it synergises with lipopolysaccharide in decreasing glycosaminoglycan synthesis when added to chondrocyte cultures simultaneously with or before lipopolysaccharide.
Materials and methods

MATERIALS
Muramyl dipeptide (Daiichi Pharmaceutical Co, Tokyo, Japan) and five synthetic muramyl dipeptide analogues were used; these analogues were synthesised as described elsewhere. '8 19 Human recombinant IL-Ict (2 5x 107 U/mg) was from Dainippon Pharmaceuticals (Osaka, Japan). Lipopolysaccharide derived from Escherichia coli 0 55:B5 and synthetic E coli lipid A (506) were purchased from Difco Laboratories (Detroit, MI, USA) and Daiichi Pure Chemicals (Tokyo, Japan) respectively. Sulphur-35 labelled sulphate (carrier free) was from the Japan Atomic Energy Research Institute (Tokyo, Japan). Other materials used were commercial products of the highest grade available. CULTURE 
PROCEDURE
Chondrocytes were obtained from the growth cartilage of ribs of four week old Wistar rats, as described by Shimomura et At the end of the labelling period the medium and cells were mixed and digested with pronase E (2 mg/ml) at 55°C for 12 hours. After digestion the precipitates with 1% cetylpyridinium chloride were collected on a Millpore filter (pore size 45 ,um) and the radioactivity retained on the filter was counted in a liquid scintillation spectrometer.
In experiments where two agents (lipopolysaccharide and muramyl dipeptide) were added sequentially, chondrocytes were exposed to the first agent for 24 hours. After removing the medium, the chondrocytes were washed twice with fresh medium and exposed to the second agent for another 24 hours. During the final six hours of culture, the chondrocytes were labelled with 37 kBq/ml of [35S]sulphate.
Results
We examined the effect of muramyl dipeptide, lipopolysaccharide, and IL-la on the glycosaminoglycan synthesis of cultured rat costal chondrocytes. When rat chondrocytes were incubated in the presence of each agent for 72 hours, lipopolysaccharide and IL-la strongly inhibited glycosaminoglycan synthesis in a dose dependent manner; muramyl dipeptide (005-50 )g/ml) had no effect on the glycosaminoglycan synthesis ( fig 1) . This result was in striking contrast to our finding that in rabbit chondrocytes muramyl dipeptide inhibited glycosaminoglycan synthesis. '7 Next we examined the possible cooperative effect of muramyl dipeptide and lipopolysaccharide as muramyl dipeptide administered in vivo has been reported to enhance the activities of lipopolysaccharide, such as induction of anaphylactoid shock reaction and lethality22 and induction of macrophage colony stimulating factor'5 in mice. Figure 2 shows that muramyl dipeptide (5 [tg/ml) strikingly enhanced the lipopolysaccharide induced inhibition of glycosaminoglycan synthesis in rat chondrocytes when muramyl dipeptide and lipopolysaccharide were added simultaneously. This synergistic effect was muramyl dipeptide dose dependent ( fig 3) . The doses for the half maximal and maximal response were approximately 0-5 ptg/ ml and 5 ig/ml, respectively. There was no evidence of a synergistic effect of muramyl dipeptide in the IL-la induced inhibition of glycosaminoglycan synthesis (data not shown).
Five synthetic muramyl dipeptide analogues which are immunoadjuvant active, or inactive'0 were tested to confirm that the enhancement of the lipopolysaccharide induced inhibition of glycosaminoglycan synthesis is due to muramyl dipeptide itself and not to other contaminations. Figure 4 shows that two immunoadjuvant active muramyl dipeptide analogues, but not inactive muramyl dipeptide analogues, also enhanced lipopolysaccharide induced inhibition of glycosaminoglycan synthesis; hence, the effect of muramyl dipeptide on glycosaminoglycan syn- Figure 6 shows that lipid A as well as lipopolysaccharide inhibited glycosaminoglycan synthesis of rat chondrocytes in a dose dependent manner. The range of doses of lipid A was similar to that oflipopolysaccharide. In addition, when muramyl dipeptide and lipid A were simultaneously added to the medium, the dose response curve of lipid A on the glycosaminoglycan synthesis shifted to the left, hence muramyl dipeptide may enhance the inhibitory effect of the lipid A portion of lipopolysaccharide on glycosaminoglycan synthesis by rat chondrocytes ( fig 6) .
Discussion
In this study we found that muramyl dipeptide, an essential structure for the immunoadjuvant activities of bacterial cell wall peptidoglycan, [6] [7] [8] [9] [10] enhanced the lipopolysaccharide induced inhibition of glycosaminoglycan synthesis, whereas muramyl dipeptide alone had no effect on the glycosaminoglycan synthesis. The cooperative effect of the synthetic muramyl dipeptide and lipopolysaccharide was seen with immunoadjuvant active analogues but not with immunoadjuvant inactive analogues. Thus 
